Healthcare Wrap: EBR plunges as sales resets collide with biotech funding needs

• EBR Systems fell 40.43% after WiSE implant volumes dropped and its sales reset delayed growth.
• Memphasys lost 20.00% despite record Felix revenue and new overseas clinic trials.
• Mesoblast’s Ryoncil sales reached US$115.2 million, but the company still expects to raise more money.
• Acrux gained 9.09% after the FDA confirmed the trial package needed for its female testosterone spray.